On 2014 Sep 01, Matthew Katz commented:

This Phase II trial by RTOG demonstrated the ability to safely deliver ablative radiation doses to offer excellent local tumor control. It has transformed the prognosis for patients with medically inoperable non-small cell lung cancer. Whether stereotactic radiation can be an alternative to surgery is currently under study on protocol. But this trials clearly supports a role for stereotactic radiation in the body as well as its known role for treating brain tumors.

Improvements have been made in dose calculation and more data now support the findings of RTOG 0236. Further study is needed to fine tune best dose schedules, technique and immobilization. Whether there is any role in node positive patients remains to be determined.

On 2014 Sep 01, Matthew Katz commented:

This Phase II trial by RTOG demonstrated the ability to safely deliver ablative radiation doses to offer excellent local tumor control. It has transformed the prognosis for patients with medically inoperable non-small cell lung cancer. Whether stereotactic radiation can be an alternative to surgery is currently under study on protocol. But this trials clearly supports a role for stereotactic radiation in the body as well as its known role for treating brain tumors.

Improvements have been made in dose calculation and more data now support the findings of RTOG 0236. Further study is needed to fine tune best dose schedules, technique and immobilization. Whether there is any role in node positive patients remains to be determined.